MEDIATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BINDING BY INTERACTION OF CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS WITH THE V3 REGION OF ENVELOPE GP120-GP41

被引:217
作者
RODERIQUEZ, G
ORAVECZ, T
YANAGISHITA, M
BOUHABIB, DC
MOSTOWSKI, H
NORCROSS, MA
机构
[1] US FDA,CTR BIOL EVALUAT & RES,DIV HEMATOL PROD,BETHESDA,MD 20892
[2] NIDR,BONE RES BRANCH,BETHESDA,MD 20892
关键词
D O I
10.1128/JVI.69.4.2233-2239.1995
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mechanism of heparan sulfate (HS)-mediated human immunodeficiency virus type 1 (HIV-1) binding to and infection of T cells was investigated with a clone (H9h) of the T-cell line H9 selected on the basis of its high level of cell surface CD4 expression. Semiquantitative PCR analysis revealed that enzymatic removal of cell surface HS by heparitinase resulted in a reduction of the amount of HIV-1 DNA present in H9h cells 4 h after exposure to virus. Assays of the binding of recombinant envelope proteins to H9h cells demonstrated a structural requirement for an oligomeric form of gp120/gp41 for HS-dependent binding to the cell surface, The ability of the HIV-1 envelope to bind simultaneously to HS and CD4 was shown by immunoprecipitation of HS with either antienvelope or anti-CD4 antibodies from (SO42-)-S-35-labeled H9h cells that had been incubated with soluble gp140. Soluble HS blocked the binding of monoclonal antibodies that recognize the V3 and C4 domains of the envelope protein to the surface of H9 cells chronically infected with HIV-1(IIIB). The V3 domain was shown to be the major site of envelope-HS interaction by examining the effects of both antienvelope monoclonal antibodies and heparitinase on the binding of soluble gp140 to H9h cells.
引用
收藏
页码:2233 / 2239
页数:7
相关论文
共 50 条
  • [1] ANDO I, 1989, Tissue Antigens, V33, P252
  • [2] BATINIC D, 1992, J BIOL CHEM, V267, P6664
  • [3] BUGELSKI PJ, 1991, J ACQ IMMUN DEF SYND, V4, P923
  • [4] DEXTRAN SULFATE BLOCKS ANTIBODY-BINDING TO THE PRINCIPAL NEUTRALIZING DOMAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITHOUT INTERFERING WITH GP120-CD4 INTERACTIONS
    CALLAHAN, LN
    PHELAN, M
    MALLINSON, M
    NORCROSS, MA
    [J]. JOURNAL OF VIROLOGY, 1991, 65 (03) : 1543 - 1550
  • [5] T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS
    CALLEBAUT, C
    KRUST, B
    JACOTOT, E
    HOVANESSIAN, AG
    [J]. SCIENCE, 1993, 262 (5142) : 2045 - 2050
  • [6] THE CD4 (T4) ANTIGEN IS AN ESSENTIAL COMPONENT OF THE RECEPTOR FOR THE AIDS RETROVIRUS
    DALGLEISH, AG
    BEVERLEY, PCL
    CLAPHAM, PR
    CRAWFORD, DH
    GREAVES, MF
    WEISS, RA
    [J]. NATURE, 1984, 312 (5996) : 763 - 767
  • [7] DEJONG JJ, 1992, J VIROL, V66, P57
  • [8] EVALUATION OF MONOCLONAL-ANTIBODIES TO HIV-1 BY NEUTRALIZATION AND SEROLOGICAL ASSAYS - AN INTERNATIONAL COLLABORATION
    DSOUZA, MP
    DURDA, P
    HANSON, CV
    MILMAN, G
    [J]. AIDS, 1991, 5 (09) : 1061 - 1070
  • [9] MULTIMERIC CD4 BINDING EXHIBITED BY HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN DIMERS
    EARL, PL
    DOMS, RW
    MOSS, B
    [J]. JOURNAL OF VIROLOGY, 1992, 66 (09) : 5610 - 5614
  • [10] BIOLOGICAL AND BIOCHEMICAL-CHARACTERIZATION OF A CLONED LEU-3- CELL SURVIVING INFECTION WITH THE ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME RETROVIRUS
    FOLKS, TM
    POWELL, D
    LIGHTFOOTE, M
    KOENIG, S
    FAUCI, AS
    BENN, S
    RABSON, A
    DAUGHERTY, D
    GENDELMAN, HE
    HOGGAN, MD
    VENKATESAN, S
    MARTIN, MA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (01) : 280 - 290